Friday, 21 September, 2018

Laidlaw Reiterates "Buy" Rating for Flexion Therapeutics, Inc. (FLXN)

Endpoints News Endpoints News
Stacy Diaz | 11 October, 2017, 03:48

(NASDAQ:FLXN), with 4 analysts believing it is a strong buy. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company's stock valued at $1,131,000 after purchasing an additional 338 shares during the last quarter.

BMO Capital "Maintained" Flexion Therapeutics (NASDAQ:FLXN) in a research note issued to investors on 10/09/17 to Outperform with price target of $37.

The average Wall Street analyst rating for Flexion Therapeutics, Strong Buy, according to the average of 4 analyst scores. ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Wednesday, June 21st. (FOX) holds the market capitalization of $- along with - outstanding shares. The stock closing price is now trading upward to its 50 day moving average with change of 25.35%, escalated to its 20 day moving average with figure of 20.00% and above its 200 day moving average with value 38.57%. Laidlaw's target price suggests a potential upside of 34.56% from the company's current price.

Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Flexion Therapeutics Inc (FLXN). The value of the total investment in Flexion Therapeutics, Inc. went from $1,503,000 to $1,284,000 a change of 14.6% since the last quarter.

Flexion Therapeutics Inc has a 50 day moving average of 24.85 and a 200 day moving average of 22.63. The company's market cap is $952.55 Million, and the average volume is 674.64 Million.

On Friday closing, Flexion Therapeutics shares surged 10.36% to $29.93.

Among 3 analysts covering AMN Healthcare (NYSE:AMN), 2 have Buy rating, 0 Sell and 1 Hold. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at -31.90%.

ILLEGAL ACTIVITY WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and global copyright laws. About 305,404 shares traded. If the published price targets set by Pandora Media, Inc. analysts have any power to influence the stock's share price, the highest price target set for P is $15. The SEC filing shows that Stejbach Mark performed a purchase of 1,580 shares. Over the last three months, insiders purchased 5,375 shares of company stock valued at $131,575.

A number of hedge funds have recently added to or reduced their stakes in FLXN. The original version of this news story can be accessed at Public Employees Retirement System of OH raised its position in Flexion Therapeutics by 69.4% during the second quarter.

Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock. IFP Advisors Inc grew its position in shares of Flexion Therapeutics by 24.5% during the second quarter. The company's price to sales ratio for trailing twelve months is 0.65 and price to book ratio for most recent quarter is 2.15, whereas price to cash per share for the most recent quarter is 12.30. Bank of New York Mellon Corp raised its holdings in shares of Flexion Therapeutics by 27.9% during the second quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company's stock worth $365,000 after buying an additional 3,200 shares during the last quarter.

The company said that the FDA approval of Zilretta is based upon data from Flexion's pivotal Phase 3 clinical trial.

Indication: ZILRETTAâ„¢ (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.